Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HER2
Biotech
ESMO: Jazz HER2 bispecific posts 59% survival at 30 months
The 30-month data unveiled at ESMO gave other insights into zanidatamab’s efficacy, including a confirmed objective response rate of 84%.
James Waldron
Sep 16, 2024 3:00am
Boehringer, Bayer advance lung cancer meds toward Enhertu battle
Sep 9, 2024 4:43pm
ALX's fizzling CD47 response rate sends stock spiraling down
Aug 1, 2024 5:34am
OS Therapies refiles $6M IPO to fund HER2 drug, preclinical ADCs
Aug 1, 2024 5:18am
Zymeworks halts phase 2 ADC plans over 'clinical landscape'
Mar 7, 2024 9:00am
Endeavor signs $430M deal for Hummingbird's HER3-targeted ADC
Oct 19, 2023 10:29am
